Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Qiagen ( (QGEN) ) has provided an announcement.
Qiagen announced its financial results for Q4 and FY 2024, showing solid growth and exceeding its sales and profitability outlook. The company reported Q4 net sales of $521 million, a 2% increase, with a 3% rise in sales at constant exchange rates. Major product lines like QIAstat-Dx and QuantiFERON exhibited double-digit growth. Qiagen’s adjusted operating income margin improved significantly, and the company expects continued growth into 2025, aiming for a 4% sales increase at constant exchange rates and improved profit margins. The results reflect Qiagen’s strong recurring revenue base and its strategic focus on profitable growth, while also achieving a significant free cash flow increase and returning approximately $300 million to shareholders through a share repurchase.
More about Qiagen
Qiagen N.V. operates in the biotechnology and life sciences industry, providing various molecular diagnostic solutions, including products like QIAstat-Dx, QuantiFERON, and QIAcuity digital PCR. The company focuses on delivering diagnostic solutions and genomic analysis tools, with a strong presence in the global market for molecular diagnostics and testing.
YTD Price Performance: -4.67%
Average Trading Volume: 979,076
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $9.24B
Find detailed analytics on QGEN stock on TipRanks’ Stock Analysis page.
